VRTX: Vertex Pharmaceuticals Incorporated Stock Live Price Graph
Vertex Pharmaceuticals Incorporated stock live price (US Dollar), charts and analysis. Get VRTX stock market news.
Vertex Pharmaceuticals Incorporated (VRTX)
Loading chart...
About the company
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Company profile
Market News & Analysis
Dividend History
No dividend or corporate action data is available for this instrument.
What Is VRTX? Live VRTX Prices and Analysis
Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company that focuses on the development and commercialization of innovative therapies for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex has made significant strides in treating cystic fibrosis (CF) and other serious diseases. Its groundbreaking treatments have not only changed the lives of patients but also attracted the attention of investors seeking potential growth in the biotechnology sector.
Investors closely follow VRTX due to its strong pipeline of drugs, robust financial performance, and the potential for future growth in both revenues and market capitalization. The company's commitment to research and development (R&D) and its strategic partnerships further enhance its position in the competitive biotech landscape.
Frequently asked questions
What is the VRTX stock price?
The latest VRTX (Vertex Pharmaceuticals Incorporated (VRTX)) stock price is 505.6400 USD. Follow the live quote and chart on this page for real-time updates.
What are VRTX's intraday ceiling and floor prices?
For VRTX, the intraday ceiling is 511.5050 USD and the floor is 503.9420 USD. These levels may update during the session.
What is VRTX's previous closing price?
The previous closing price for VRTX is 502.3100 USD.
What is VRTX's trading volume?
The current trading volume for VRTX is 806,603. Volume can change throughout the session.
Where can I see the live VRTX price?
You can follow the live VRTX (Vertex Pharmaceuticals Incorporated (VRTX)) price in the quote area and chart at the top of this Investvio overview page.
Where can I see VRTX historical prices and charts?
The current price chart for VRTX (Vertex Pharmaceuticals Incorporated (VRTX)) is on this overview page. For longer historical prices and archive data, open the Archive tab and choose a period to review past performance.